Momenta Pharmaceuticals, Inc. - TheStreet
TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

LATEST NEWS

No More Tears for Johnson & Johnson?
Play
INVESTING

Johnson & Johnson Halts Development of Flu Treatment Candidate

PRESS RELEASES

ALERT: Halper Sadeh LLP Is Investigating The Following Mergers; Shareholders Are Encouraged To Contact The Firm

PRESS RELEASES

Momenta Pharmaceuticals Announces Expiration Of Hart-Scott-Rodino Waiting Period In Connection With Proposed Sale To Johnson & Johnson

No More Tears for Johnson & Johnson?
INVESTING

Johnson & Johnson Halts Development of Flu Treatment Candidate

PRESS RELEASES

SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Investigates The Following Mergers; Shareholders Are Encouraged To Contact The Firm - MVC, PRNB, YIN, MNTA

Jim Cramer: Johnson & Johnson Will Do Well With Actelion
INVESTING

Johnson & Johnson Sets Late-Stage Vaccine Trial Next Month

PRESS RELEASES

Moore Kuehn Encourages NTN, PRNB, MNTA, And PFNX Investors To Contact Law Firm

PRESS RELEASES

MOMENTA INVESTOR ALERT By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy Of Price And Process In Proposed Sale Of Momenta Pharmaceuticals, Inc. - MNTA

PRESS RELEASES

SHAREHOLDER ALERT: WeissLaw LLP Investigates Momenta Pharmaceuticals, Inc.

PRESS RELEASES

INVESTOR ALERT: Monteverde & Associates PC Announces An Investigation Of Momenta Pharmaceuticals, Inc. - MNTA

No More Tears for Johnson & Johnson?
INVESTING

Could Momenta Deal Give Johnson & Johnson Breakout Momentum?

PRESS RELEASES

MOMENTA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale Of MNTA And Encourages Investors To Contact The Firm

J&J, Eli Lilly Healthy for Your Portfolio Says Causeway Global Manager
Video

Johnson & Johnson Gains Drugmaker Momenta in $6.5B Deal

  • Aug 19, 2020 9:55 AM EDT
PRESS RELEASES

(MNTA) Alert: Johnson Fistel Investigates Proposed Sale Of Momenta Pharmaceuticals; Are Shareholders Getting A Fair Price?

Stocks Open Higher on Positive Earnings from J&J, Coca-Cola
MERGERS AND ACQUISITIONS

Johnson & Johnson to Buy Momenta Pharmaceuticals for $6.5 Billion

PRESS RELEASES

Momenta Pharmaceuticals Announces Date Of Second Quarter 2020 Financial Results Conference Call And Webcast

PRESS RELEASES

Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation For Nipocalimab In HDFN

PRESS RELEASES

Momenta Pharmaceuticals Announces Positive Topline Data From Interim Analysis Of Phase 2 Vivacity-MG Study Of Nipocalimab (M281) In Generalized Myasthenia Gravis (gMG)

PRESS RELEASES

Momenta Pharmaceuticals Announces Date Of First Quarter 2020 Financial Results Conference Call And Webcast

PRESS RELEASES

Momenta Provides Corporate Update Amid COVID-19 Pandemic

PRESS RELEASES

Momenta Pharmaceuticals To Webcast Presentation At The Cowen 40th Annual Health Care Conference

PRESS RELEASES

Momenta Pharmaceuticals Announces Date Of Fourth Quarter And Year End 2019 Financial Results Conference Call And Webcast

Roche CEO Bullish on U.S. Drug Market
INVESTING

Momenta Rockets After Analysts Get Bullish on Biopharma's Newest Treatment

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug
STOCKS

Teva shares fall as FDA OKs another generic version of multiple sclerosis drug

Mylan First-Quarter Revenue Misses Estimate Amid Lower Sales of Branded Product
STOCKS

States Target Mylan President, Emcure Exec in Generic Drug Lawsuit